Suvratoxumab is under clinical development by Aridis Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Suvratoxumab’s likelihood of approval (LoA) and phase transition for Ventilator Associated Pneumonia (VAP) took place on 19 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Suvratoxumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Suvratoxumab (MEDI-4893) is under development for the prevention of ventilator associated pneumonia caused by Staphylococcus aureus. The drug candidate is administered intravenously in the form of solution. It is a potent human Immunoglobulin G (IgG)1 monoclonal antibody that binds to an alpha toxin released by Staphylococcus aureus. It is a new molecular entity.
Aridis Pharmaceuticals overview
Aridis Pharmaceuticals (Aridis) is a biopharmaceutical company. The company develops novel, differentiated therapies for infectious diseases. Its pipeline products include AR-301 mAb, AR-105 mAb, AR-101 mAb, AR-501(Gallium Citrate), AR-401 mAb and AR-201 mAb. The company uses a disruptive platform technology to discover potent human monoclonal antibodies from patients. Its proprietary platform, MabIgXis used to discover potent therapeutic antibodies for any diseases and to generate an unrivaled product portfolio ofanti-infective mAbs. The company also works on macromolecular stabilization technology for increase the stability of vaccines. Aridis is headquartered in San Jose, California, the US
Quick View Suvratoxumab LOA Data
|Highest Development Stage|